(firstQuint)P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne.

 This is a double-blind, placebo controlled study in subjects with moderate to severe acne.

 Subjects who satisfy the entry criteria will be randomized to SB204 4% QD or Vehicle Gel QD in a 1:1 ratio.

 Efficacy assessments will include Investigator Global Assessments (IGA) and inflammatory and non-inflammatory lesion counts.

 Subjects will return for post-Baseline evaluation at Weeks 2, 4, 8, and 12/Early Termination (ET).

.

 P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne@highlight

This is a 12 week, multi-center, double-blinded, randomized, vehicle-controlled, parallel group, study to be conducted in approximately 1300 subjects with acne vulgaris in the US.

